Pahr Therapeutics is a technology company.
PAhR Therapeutics is a clinical-stage company focused on developing novel mechanisms for the treatment of pulmonary arterial hypertension (PAH).
Pahr Therapeutics has raised $14.0M across 1 funding round.
Pahr Therapeutics has raised $14.0M in total across 1 funding round.
Pahr Therapeutics has raised $14.0M in total across 1 funding round.
Pahr Therapeutics's investors include Insight Partners, RA Capital.
The premise of your query is incorrect: Pahr Therapeutics is not a technology company—it is a clinical-stage biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH).[2][3]
Pahr Therapeutics is a privately-held clinical-stage biotech company developing innovative biological treatments for pulmonary arterial hypertension, a serious cardiovascular disease affecting the lungs.[2][3] The company addresses a critical unmet medical need by pursuing novel therapeutic mechanisms for PAH patients. In July 2025, Pahr Therapeutics raised $14 million in seed financing led by RA Capital Management, AN Venture Partners, and University of Tokyo Edge Capital Partners (UTEC), demonstrating strong investor confidence in its approach.[4]
Pahr Therapeutics was incubated at Raven, the venture incubator of RA Capital Management, and is led by Neil Buckley, a Venture Partner at Raven.[4] The company was co-founded by three accomplished researchers from Japan's National Cerebral and Cardiovascular Center (NCVC) in Osaka: Dr. Yoshikazu Nakaoka (Director of the Vascular Physiology department), Dr. Makoto Okazawa, and Dr. Ryotaro Asano.[4] Dr. Nakaoka has conducted pioneering research in the molecular pathophysiology of PAH for years, and his group's research directly informed the company's novel therapeutic approaches.[4]
Pahr Therapeutics represents the growing trend of international biotech collaboration, bridging Japanese academic research excellence with global venture capital and operational expertise. The company addresses pulmonary arterial hypertension, a rare but serious disease with limited treatment options, positioning it within the broader movement toward rare disease therapeutics. The involvement of RA Capital Management—known for building biotech companies from inception—signals confidence in both the scientific foundation and the team's ability to execute clinical development.
Pahr Therapeutics is well-positioned to advance its lead programs into clinical trials in 2026, with strong financial backing and world-class scientific leadership. The company's success will depend on demonstrating clinical efficacy in PAH patients and navigating the regulatory pathway to approval. As a rare disease-focused biotech, it operates in a favorable market environment where unmet medical needs command premium valuations and regulatory pathways are often more streamlined than for common diseases.
Pahr Therapeutics has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $14.0M Seed | Insight Partners, RA Capital |